RT Journal Article
SR Electronic
T1 The causes and consequences of Alzheimer’s disease: phenome-wide evidence from Mendelian randomization
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2019.12.18.19013847
DO 10.1101/2019.12.18.19013847
A1 Roxanna Korologou-Linden
A1 Emma L Anderson
A1 Laura D Howe
A1 Louise A C Millard
A1 Yoav Ben-Shlomo
A1 Dylan M Williams
A1 George Davey Smith
A1 Evie Stergiakouli
A1 Neil M Davies
YR 2020
UL http://medrxiv.org/content/early/2020/03/16/2019.12.18.19013847.abstract
AB Importance Alzheimer’s disease is the leading cause of disability and healthy life years lost. However, to date, there are no proven causal and modifiable risk factors, or effective interventions.Objective We aimed to identify: a) factors modified by prodromal Alzheimer’s disease pathophysiology and b) causal risk factors for Alzheimer’s disease. We identified factors modified by Alzheimer’s disease using a phenome-wide association study (PheWAS) on the Alzheimer’s disease polygenic risk score (PRS) (p≤5×10−8), stratified by age tertiles. We used two-sample bidirectional Mendelian randomization (MR) to estimate the causal effects of identified risk factors and correlates on liability for Alzheimer’s disease.Design, setting, and participants 334,968 participants of the UK Biobank aged 39 to 72 years old (111,656 in each tertile) met our eligibility criteria.Exposures Standardized weighted PRS for Alzheimer’s disease at p≤5×10−8.Main outcomes and measures All available phenotypes in UK Biobank, including data on health and lifestyle, as well as samples from urine, blood and saliva, at the time of analysis.Results Genetic liability for Alzheimer’s disease was associated with red blood cell indices and cognitive measures at all ages. In the middle and older age tertiles, ages 53 and above, higher genetic liability for Alzheimer’s disease was adversely associated with medical history (e.g. atherosclerosis, use of cholesterol-lowering medications), physical measures (e.g. body fat measures), blood cell indices (e.g. red blood cell distribution width), cognition (e.g. fluid intelligence score) and lifestyle (e.g. self-reported moderate activity). In follow-up analyses using MR, there was only evidence that education, fluid intelligence score, hip circumference, forced vital capacity, and self-reported moderate physical activity were likely to be causal risk factors for Alzheimer’s disease.Conclusion and relevance Genetic liability for Alzheimer’s disease is associated with over 160 phenotypes, some as early as age 39 years. However, findings from MR analyses imply that most of these associations are likely to be a consequence of prodromal disease or selection, rather than a cause of the disease.Question How does higher genetic liability for Alzheimer’s disease affect the phenome across the life course and do any phenotypes causally affect incidence of disease?Finding In this population-based cohort study of 334,968 participants, higher genetic risk for Alzheimer’s disease was associated with medical history (e.g. higher odds of diagnosis of atherosclerotic heart disease), cognitive (e.g. lower fluid intelligence score), physical (e.g. lower forced vital capacity) and blood-based measures (e.g. lower haematocrit) as early as 39 years of age.Meaning Most of the identified phenotypes are likely to be symptoms of prodromal Alzheimer’s disease, rather than causal risk factors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant from the BRACE Alzheimer’s charity (BR16/028). It is part of a project entitled ‘social and economic consequences of health: causal inference methods and longitudinal, intergenerational data’, which is part of the Health Foundation’s Social and Economic Value of Health Research Programme (Award 807293). The Health Foundation is an independent charity committed to bringing about better health and health care for people in the UK. RKL was supported by a Wellcome Trust PhD studentship (Grant ref: 215193/Z18/Z). The Medical Research Council (MRC) and the University of Bristol support the MRC Integrative Epidemiology Unit [MC_UU_12013/1, MC_UU_12013/9, MC_UU_00011/1]. NMD is supported by an Economics and Social Research Council (ESRC) Future Research Leaders grant [ES/N000757/1] and the Norwegian Research Council Grant number 295989. LDH is funded by a Career Development Award from the UK Medical Research Council (MR/M020894/1). LACM is funded by a University of Bristol Vice-Chancellor’s Fellowship.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data in the current study were partly provided by the UK Biobank Study (www.ukbiobank.ac.uk), received under UK Biobank application no. 16729. Scripts are available on Github at: https://github.com/rskl92/AD_PHEWAS_UKBIOBANK.